Novo Nordisk A/S (NOVO-B.CO) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. NOVO-B.CO files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 10.43% | 30.00% | Pass |
| Interest-bearing investments | 2.02% | 30.00% | Pass |
| Non-permissible income | 0.41% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 25.70% | 33.00% | Pass |
| Interest-bearing investments | 4.97% | 33.00% | Pass |
| Non-liquid assets | 81.98% | at least 20.00% | Pass |
| Non-permissible income | 0.41% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 25.70% | 33.33% | Pass |
| Cash + interest-bearing securities | 4.97% | 33.33% | Pass |
| Accounts receivable | 18.02% | 33.33% | Pass |
| Non-permissible income | 0.41% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 25.70% | 33.33% | Pass |
| Cash + interest-bearing securities | 4.97% | 33.33% | Pass |
| Accounts receivable | 18.02% | 50.00% | Pass |
| Non-permissible income | 0.41% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 7.09% | 33.00% | Pass |
| Cash + interest-bearing securities | 1.37% | 33.00% | Pass |
| Accounts receivable | 3.60% | 33.00% | Pass |
| Non-permissible income | 0.41% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 5.63% | 33.00% | Pass |
| Cash + interest-bearing securities | 1.09% | 49.00% | Pass |
| Accounts receivable | 2.86% | 49.00% | Pass |
| Non-permissible income | 0.41% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 5.63% | 33.33% | Pass |
| Cash + interest-bearing securities | 1.09% | 33.33% | Pass |
| Accounts receivable | 3.95% | 49.00% | Pass |
| Non-permissible income | 0.41% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 40.30 | NEUTRAL |
| Stochastic %K (14) | 4.07 | BUY |
| CCI (20) | -152.74 | BUY |
| Williams %R (14) | -95.93 | BUY |
| MACD (12,26,9) | -0.28 | SELL |
| ROC (10) | -6.14 | SELL |
| Momentum (10) | -18.90 | SELL |
| EMA (10) | 295.95 | SELL |
| SMA (10) | 296.50 | SELL |
| EMA (20) | 298.28 | SELL |
| SMA (20) | 297.11 | SELL |
| EMA (30) | 299.95 | SELL |
| SMA (30) | 299.83 | SELL |
| EMA (50) | 300.22 | SELL |
| SMA (50) | 308.50 | SELL |
| EMA (100) | 296.59 | SELL |
| SMA (100) | 294.21 | SELL |
| EMA (200) | 300.78 | SELL |
| SMA (200) | 291.36 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - General
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Background via Yahoo Finance — informational, not part of the verdict.
Research only, not the primary verdict above — SEC EDGAR (the source for the main in-house research card, if shown) has no data for this symbol, so this is computed from a real, country-specific filing instead. Business-activity screening isn't part of this check.
Based on the filing period ending 2026-06-30, figures in DKK.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
